11.12.2024 22:15:00
|
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE) --
Paris, France, December 11, 2024
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
Date | Number of Shares Outstanding | Total number of voting rights | |
Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
November 30, 2024 | 47,426,851 | 49,202,229 | 49,180,111 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
Media Relations | |
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com |
________________________
1 The total number of theoretical (or "gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or "net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
Mut zum Risiko – BX Morningcall mit Dr. Ralf Seiz & François Bloch
🔔🔔🔔
Im heutigen BX Morningcall Spezial gibt Dr. Ralf Seiz, CEO und Gründer der Finreon AG, spannende Einblicke in innovative Anlagelösungen. Als Spin-off der Universität St. Gallen bietet Finreon Strategien an, die Diversifikation und Risikomanagement vereinen – unter anderem durch die systematische Reduktion von Aktienkonzentrationen und die Nutzung von Volatilitätsprämien.Zusammen mit dem Investmentstrategen François Bloch und Olivia Hähnel von BX Swiss spricht der promovierte Ökonom auch über die aktuellen wirtschaftlichen Herausforderungen und gibt exklusive Einblicke in seine persönlichen Anlageprojekte.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
SNB senkt Leitzins überraschend deutlich: SMI beendet Handel im Plus -- DAX schliesst fester -- Wall Street schliesslich in Rot -- Asiens Börsen letztendlich höherDer heimische Aktienmarkt zeigte sich am Donnerstag mit leichten Gewinnen. Der deutsche Aktienmarkt präsentierte sich letztendlich ebenso höher. Anleger an der Wall Street hielten sich in Deckung. In Fernost dominierten die Käufe das Geschehen.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |